Seeking Alpha

TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO...

TPG's acquisition of Immucor (BLUD +30%) fails to spur comparables Bio-Rad Laboratories (BIO -0.7%) and Gen-Probe (GPRO -1.1%). Takeout multiples were below current diagnostics multiples, Leerink notes, and the P-E buyout likely means there was little interest in BLUD from strategic acquirers.
From other sites
Comments (1)
  • Ed's perspective
    , contributor
    Comments (262) | Send Message
     
    RE: likely means there was little interest in BLUD from strategic acquirers.

     

    since they just came thru a dept of justice analysis looking into monopoly issues ... why would anyone even THINK a strategic partner could afford to consolidate even more market share.

     

    Any strategic partner would only have indirect marketing similarities... and thus synergy effects would be diluted.
    12 Jul 2011, 08:43 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs